Alto Neuroscience/$ANRO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
- Ticker
- $ANRO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 68
- Headquarters
- Mountain View, United States
- Website
- www.altoneuroscience.com
ANRO Metrics
BasicAdvanced
$1.2B
-
-$2.36
1.45
-
Price and volume
Market cap
$1.2B
Beta
1.45
52-week high
$37.48
52-week low
$10.80
Average daily volume
620K
Financial strength
Current ratio
18.121
Quick ratio
17.904
Long term debt to equity
0.041
Total debt to equity
0.061
Interest coverage (TTM)
-48.48%
Profitability
EBITDA (TTM)
-99.841
Management effectiveness
Return on assets (TTM)
-26.54%
Return on equity (TTM)
-46.65%
Valuation
Price to book
4.2
Price to tangible book (TTM)
4.2
Price to free cash flow (TTM)
-15.749
Free cash flow yield (TTM)
-6.35%
Free cash flow per share (TTM)
-1.978
Growth
Earnings per share change (TTM)
2.47%
3-year earnings per share growth (CAGR)
-35.58%
What the Analysts think about ANRO
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
Analyst projections of the future price of Alto Neuroscience stock.
Bulls say / Bears say
An independent, placebo-controlled study published in Nature Medicine found that pramipexole significantly reduced anhedonia, supporting the drug mechanism behind ALTO-207. Alto’s combination is designed to reduce the nausea that often limits pramipexole dosing, although that benefit still needs to be proven in its own trials. (Alto Neuroscience, Inc.)
Alto is developing ALTO-207 for both adjunctive and monotherapy use in treatment-resistant depression, with Phase 3 trials planned alongside an ongoing Phase 2b study. If the drug works, success across both settings could widen its potential use; the Phase 2b readout is expected in the second half of 2027. (Alto Neuroscience, Inc.)
After a July share offering, Alto reported pro forma cash of about $338 million and expects it to fund planned operations through 2030. That gives the company room to advance ALTO-207 and reach several pipeline readouts without an immediate need for more capital. (Alto Neuroscience, Inc.)
ALTO-101 failed to meet its Phase 2 trial’s primary EEG outcome in schizophrenia-related cognitive impairment. Positive findings came from later or subgroup analyses, so the overall result leaves doubt about the candidate’s clinical value. (Alto Neuroscience, Inc.)
After reviewing an earlier ALTO-100 depression study, Alto tightened eligibility and data checks in its ongoing ALTO-100 and ALTO-300 trials; the added screening pushed both readouts into 2027. The changes may improve data quality, but they also point to execution risks and a longer wait for results. (Alto Neuroscience, Inc.)
Alto remains loss-making as it expands trials: its second-quarter net loss widened to $27.6 million from $17.7 million a year earlier. It raised about $100 million by issuing 3.78 million shares in July, showing that funding growth can dilute existing holders even with substantial cash on hand. (Alto Neuroscience, Inc., Alto Neuroscience, Inc.)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
ANRO Financial Performance
Revenues and expenses
ANRO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ANRO News
AllArticlesVideos
Funds containing ANRO
Fund name | Fund size | $ANRO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.